Agenus Historical Cash Flow
| AGEN Stock | USD 3.42 0.07 2.01% |
Analysis of Agenus cash flow over time is an excellent tool to project Agenus Inc future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 190.4 M or Other Cashflows From Financing Activities of 190.9 K as it is a great indicator of Agenus ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Agenus Inc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Agenus Inc is a good buy for the upcoming year.
Agenus |
About Agenus Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Agenus balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Agenus's non-liquid assets can be easily converted into cash.
Agenus Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Agenus Inc to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Agenus operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Agenus' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Agenus Inc current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agenus Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. At this time, Agenus' Stock Based Compensation is very stable compared to the past year. As of the 29th of November 2024, Investments is likely to grow to about 3.6 M, though Change In Cash is likely to grow to (96.5 M).
Agenus cash flow statement Correlations
Click cells to compare fundamentals
Agenus Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Agenus cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 8.8M | 40.7M | 192.1M | (113.3M) | (101.6M) | (96.5M) | |
| Free Cash Flow | (23.3M) | (142.6M) | (23.7M) | (228.4M) | (234.2M) | (222.4M) | |
| Change In Working Capital | 58.7M | 9.0M | (9.7M) | 24.1M | 10.8M | 11.3M | |
| Begin Period Cash Flow | 53.1M | 61.8M | 102.5M | 294.6M | 181.3M | 190.4M | |
| Other Cashflows From Financing Activities | 31.6M | 4.5M | 16.7M | 898K | 201K | 191.0K | |
| Depreciation | 6.7M | 7.2M | 6.8M | 6.9M | 13.6M | 14.3M | |
| Other Non Cash Items | 17.6M | 14.3M | 31.7M | 5.9M | (25.7M) | (24.4M) | |
| Capital Expenditures | 4.7M | 3.5M | 33.8M | 53.1M | 10.0M | 7.4M | |
| Total Cash From Operating Activities | (18.7M) | (139.1M) | 10.1M | (175.4M) | (224.2M) | (213.0M) | |
| Net Income | (111.6M) | (182.9M) | (28.7M) | (230.7M) | (245.8M) | (233.5M) | |
| Total Cash From Financing Activities | 31.3M | 183.9M | 225.3M | 95.8M | 119.9M | 70.1M | |
| End Period Cash Flow | 61.8M | 102.5M | 294.6M | 181.3M | 79.8M | 69.2M | |
| Change To Inventory | 24K | 55K | 3.6M | (6.2M) | (7.1M) | (6.8M) | |
| Change To Liabilities | 6.9M | (8.7M) | (11.0M) | 8.5M | 7.7M | 8.1M | |
| Total Cashflows From Investing Activities | (4.7M) | (4.4M) | (43.2M) | (33.6M) | (30.2M) | (28.7M) | |
| Change To Account Receivables | (15.4M) | 16.2M | (394K) | 122K | (23.5M) | (22.3M) | |
| Sale Purchase Of Stock | 30M | 176.4M | (1.7M) | (3.8M) | (4.6M) | (4.3M) | |
| Stock Based Compensation | 9.9M | 10.4M | 19.6M | 18.3M | 22.9M | 24.0M | |
| Investments | (4.7M) | (4.4M) | (15.0M) | 371K | 3.4M | 3.6M | |
| Change Receivables | (15.4M) | 16.2M | (394K) | 122K | 140.3K | 147.3K | |
| Net Borrowings | (320K) | 3.0M | (1.3M) | (490K) | (441K) | (463.1K) | |
| Cash And Cash Equivalents Changes | 8.0M | 40.3M | 192.3M | (113.2M) | (130.1M) | (123.6M) | |
| Cash Flows Other Operating | 36.7M | (58.0M) | (63.5M) | (30.7M) | (27.6M) | (26.3M) | |
| Change To Netincome | 58.0M | 25.7M | 37.0M | 70.4M | 81.0M | 85.0M | |
| Change To Operating Activities | 20.3M | 1.5M | 1.7M | 27.8M | 32.0M | 33.6M | |
| Issuance Of Capital Stock | 30M | 176.4M | 220.6M | 99.2M | 133.2M | 136.4M |
Pair Trading with Agenus
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agenus position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agenus will appreciate offsetting losses from the drop in the long position's value.Moving against Agenus Stock
| 0.89 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.79 | ESPR | Esperion Therapeutics | PairCorr |
| 0.7 | VTRS | Viatris | PairCorr |
| 0.68 | GILD | Gilead Sciences | PairCorr |
| 0.65 | EWTX | Edgewise Therapeutics | PairCorr |
The ability to find closely correlated positions to Agenus could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agenus when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agenus - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agenus Inc to buy it.
The correlation of Agenus is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agenus moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agenus Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agenus can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agenus Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agenus. If investors know Agenus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agenus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.02) | Revenue Per Share 7.808 | Quarterly Revenue Growth 0.033 | Return On Assets (0.22) | Return On Equity (12.79) |
The market value of Agenus Inc is measured differently than its book value, which is the value of Agenus that is recorded on the company's balance sheet. Investors also form their own opinion of Agenus' value that differs from its market value or its book value, called intrinsic value, which is Agenus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agenus' market value can be influenced by many factors that don't directly affect Agenus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agenus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Agenus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agenus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.